Keyword Index Volume 28 (2016)
ADRs 13
adverse drug reaction 25
Adverse drug reactions (ADRs) 115
adverse events 101, 163
analgesic nephropathy 189
analgesics 189
animal studies 1
antidepressants 125
antidiabetic drugs 197
antiretroviral agents 13
attitude 25
Autism spectrum disorder 125
bias 221
biologics 45
biosimilars 45
chronic renal impairment 189
citalopram 33
clinical trial methodology 101
Cochrane 221
conflicts of interest 221
defensive medicine 213
depression 33, 143
disclosure 93
drug approvals 197
drug promotion 221
drug safety 101,197
education 65
efficacy 45
epidemiology and detection 163
escitalopram 33
ethical standards 221
evidence 221
extrapolation 45
FDA 33, 197
general practitioners 25
ghostwriting 33
health care costs 213
health professionals 77
health system 221
heart failure 181
imipramine 143
immunogenicity 45
independent 221
interchangeability 45
Iran 25
key-opinion-leaders 33
knowledge 25
length of stay 181
long lasting harm 1
market discontinuations 197
measurement/epidemiology 163
medical education 61
medical error 93, 163
medical malpractice 213
medication errors 77
medicine information 221
morbidity and mortality meeting 65
NAFDAC 13
neurodevelopmental delay 125
neurodevelopmental spectrum disorders 125
Nigeria 77
non-steroidal anti-inflammatory agents 181
obligation 93
office staff 61
orthopaedic surgery 65
paroxetine 143
patient relationships 61
patient safety incidents 65
patient safety 65, 163
permanent sexual dysfunction 1
pharmaceutical policy 221
pharmacovigilance 13, 115
post marketing drug safety 115
practice 25
pregnancy 125
psychiatric litigation 33
psychotropic drugs 101
relapse 143
reporting 25
research misconduct 33
risk management 163
Russia 221
safety culture 163
safety 45
selective serotonin reuptake inhibitors (SSRIs) 1
serotonin reuptake inhibitors 125
signals 13, 115
SSRI antidepressants 33
SSRIs 143
systematic review 1
taper phase 143
tort reform 213
